Browse the evidence

A significantly higher rate of patients from the pure Semaglutide group achieved the ten percent (50.54% vs. 44.64%) and fifteen percent (21.42% vs. 12.78%) weight loss thresholds compared to the compounded Semaglutide group.

Practitioners should note that pure Semaglutide may lead to better outcomes in achieving significant weight loss thresholds.

Lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity.

Practitioners should prioritize lifestyle interventions in obesity treatment plans.

The American Gastroenterological Association recommended adding pharmacologic agents to lifestyle interventions for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions alone.

Practitioners should consider pharmacologic options for patients not responding to lifestyle changes.

Surgical treatment of obesity achieves the greatest long-term weight loss compared to conservative treatment.

Practitioners should consider surgical options for patients seeking significant long-term weight loss.

The category of weight loss had significantly greater decreases in hunger and increases in flexible dietary restraint compared to the categories of weight stability and weight gain.

Weight loss may be associated with improved hunger management and dietary restraint.

The partial inpatient obesity complex therapy in an internal medicine day clinic is an effective method for sustained weight reduction in patients with obesity III°.

Practitioners can consider this therapy as a viable option for managing severe obesity.

Responders achieved an absolute weight loss of 27.1 kg (approximately 20%), while non-responders lost 8.8 kg.

Practitioners can expect significant weight loss in a substantial portion of patients undergoing this therapy.

Clinical trials have demonstrated effectiveness in lowering HbA1c and body weight.

Evidence from clinical trials supports the use of Tirzepatide for improving glycemic control and reducing body weight.

Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.

Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.

Several newer anti-obesity medications (AOMs) have been shown to reduce body weight significantly.

Clinicians can consider newer AOMs as effective options for weight management in obese patients.

The addition of 500 kcal·d −1 from whole foods/snacks in combination with a rigorous resistance training program promotes a weight gain of ~0.22 kg·wk −1, primarily as lean body mass, over 10 weeks in both male and female athletes.

Athletes looking to gain weight should consider increasing their caloric intake by 500 kcal·d −1 along with a structured resistance training program.

The peanut-based whole foods/snacks group gained less total body mass compared to the high-carbohydrate, peanut-free snack group.

Athletes may need to consider the type of snacks they consume for optimal weight gain results.

35% of protein supplement users take them for muscle mass increase.

Practitioners should emphasize muscle gain in discussions about protein supplementation.

Carbohydrate intake was below the recommended range for power athletes at each timepoint.

Athletes should increase carbohydrate intake to meet performance needs.

A very low-energy diet is an effective method for achieving glycaemic control and weight loss.

Implementing very low-energy diets may benefit patients with diabetes and obesity preoperatively.

Bariatric-metabolic procedures can improve and induce remission of diabetes mellitus.

Consider bariatric-metabolic procedures as a treatment option for patients with diabetes.

The RESTART trial aims to evaluate whether a complex lifestyle intervention can improve and maintain cardiorespiratory fitness, muscle strength, and body composition among older adults with elevated cardiometabolic risk.

Practitioners can consider implementing complex lifestyle interventions to improve fitness and health in older adults at risk.

Secondary and tertiary outcomes include parameters such as muscle strength, physical activity levels, body composition, and health-related quality of life.

Practitioners should consider these additional outcomes when evaluating the impact of lifestyle interventions.

Weight decreases of 1.0% to 2.9%, 3.0% to 4.9%, and 5.0% or greater are associated with a lower risk of type 2 diabetes by 16%, 25%, and 26%, respectively.

Encouraging weight loss can significantly reduce the risk of developing type 2 diabetes.

Preventing weight gain and reducing weight are important for lowering the risk of type 2 diabetes in individuals with a BMI of 22 or greater.

Healthcare providers should focus on weight management strategies for individuals at risk of type 2 diabetes.

Mean weight loss among patients taking liraglutide for at least 3 months was 7.6 kg (7.9%).

Liraglutide can be an effective part of a weight management plan for patients with obesity.

Patients treated for more than 6 months lost significantly more weight (8.6 kg) compared to those treated for less than 6 months (6.2 kg).

Longer treatment with liraglutide may lead to greater weight loss.

Liraglutide, along with lifestyle intervention, is a good option for weight management in the majority of patients with obesity.

Integrating liraglutide with lifestyle changes can improve weight management outcomes.

Weight reduction can be achieved with a range of energy-restricted diets, including low-fat, high-carbohydrate diets and low-carbohydrate, high-fat diets.

Implement various energy-restricted diets to facilitate weight loss based on individual preferences.